A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
Acute Myocardial Infarction
About this trial
This is an interventional prevention trial for Acute Myocardial Infarction focused on measuring Myocardial infarction, Coronary angioplasty, PARP inhibitor, PARP inhibition, Heart Attack
Eligibility Criteria
Inclusion Criteria: Subjects with acute myocardial infarction (as defined in protocol) with onset within 24 hours prior to randomization. Scheduled for primary percutaneous coronary intervention within 3 hours of presentation at a hospital participating in this study. Males and non-pregnant, non-lactating females. Exclusion Criteria: Subjects will be required to undergo a full medical review in order to exclude serious medical, or psychological illness prior to inclusion. History of a hypersensitivity reaction to more than three drugs or mannitol. Participation in any investigational study within 30 days of randomization Treatment with certain restricted medications within a specified time prior to participation in the study.
Sites / Locations
- Holy Cross Hospital
- Porter Hospital
- St. Paul Heart Clinic
- Toledo Hospital
- Hospital of the University of Pennsylvania
- Black Hills Cardiovascular Research
- Sentara Norfolk General Hospital
- West Virginia University
- Rambam Medical Center
- Meir Medical Center
- Hasharon Medical Center
- Rabin Medical Center
- Assaf Harofe Medical Centre